



## Information on the total number of voting rights and shares comprising the share capital on May 14, 2025

*Article R.22-10-23 of the French commercial code  
Lyon – France*

In the context of its combined Annual General Meeting on June 20, 2025, in compliance with article R. 22-10-23 of the French Commercial Code, **MaaT Pharma (EURONEXT: MAAT – the “Company”)** hereby declares the number of shares comprising the share capital and the total number of voting rights (Article L. 233-8 of the French Commercial Code (Code de commerce) and Article 223-16 of the General Regulations of French Autorité des Marchés Financiers (AMF)) on May 14, 2025 (ie on publication date of the notice of meeting).

**Listing place:** Euronext Paris

**ISIN code:** FR0012634822

**Website:** [www.maatpharma.com](http://www.maatpharma.com)

Date	Total number of shares comprising the share capital	Total number of theoretical voting rights <sup>(1)</sup>	Total number of effective voting rights <sup>(2)</sup>
05/14/2025	16 115 251	16 115 251	16 082 213

*(1) In accordance with Article 223-11 of the AMF General Regulation, this number is calculated on the basis of all shares to which voting rights are attached, including shares whose voting rights have been suspended.*

*(2) Effective voting rights correspond to the total number of voting rights that may be used at a General Meeting. The total number of effective voting rights is calculated without taking into account the shares with suspended voting rights.*